Compare iShares MSCI South Africa ETF (EZA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Tango Therapeutics Inc. — how do they compare? iShares MSCI South Africa ETF trades at $63.18 (market cap $465.74M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 8.1× iShares MSCI South Africa ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 73 Days and Tango Therapeutics Inc. for 0 Days on average.
| EZA | TNGX | |
|---|---|---|
Market Cap | $465.74M | $3.75B |
Volume | 245,187 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $32.90 |
52-Week Low | $60.43 | $7.50 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $64.32, up 0.86% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF, which tracks South African equities, faces headwinds from global reflation and higher capital costs impacting its financial and commodity-heavy holdings. Recent news highlighted a brief move above the 50-day average, but macro concerns dominate the narrative.
The outlook remains cautious due to exposure to volatile sectors like gold and banking amid rising rates. Investment opportunity hinges on South Africa's economic stability, but risks include commodity price pressures and unfavorable yield dynamics. Investor sentiment is neutral to bearish, with technicals suggesting near-term resistance at $64.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
